Thierry Lequerre

Summary

Affiliation: Rouen University Hospital
Country: France

Publications

  1. ncbi Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia
    Thierry Lequerre
    Department of Rheumatology, Rouen University Hospital and Inserm 905 and Institut Fédératif de Recherche Multidisciplinaire sur les Peptides 23, Institute for Biomedical Research, University of Rouen, 76031 Rouen Cedex, France
    Arthritis Res Ther 11:R99. 2009
  2. ncbi Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra)
    Carine Bansard
    Department of Rheumatology, University of Rouen, 76031 Rouen Cedex, France
    Rheumatology (Oxford) 50:283-92. 2011
  3. ncbi A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs
    Ginette Tenga
    Department of Pharmacy, Rouen University Hospital, 76031 Rouen Cedex, France
    Joint Bone Spine 78:50-5. 2011
  4. ncbi Smoking and inflammatory diseases
    Olivier Vittecoq
    Department of Rheumatology, Rouen University Hospital and Inserm U905, Rouen, France
    Best Pract Res Clin Rheumatol 22:923-35. 2008
  5. ncbi Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort
    Xavier Le Loet
    Rheumatology Department, Rouen University Hospital and Inserm Unit 905, University of Rouen, France
    Rheumatology (Oxford) 50:1901-7. 2011
  6. ncbi Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept
    Céline Blache
    INSERM, U905, Institut Fédératif de Recherche Multidisciplinaire surles Peptides 23, Institute for Biomedical Research, University of Rouen, Faculte de Medecine Pharmacie, Rouen, France
    Rheumatology (Oxford) 50:1814-22. 2011
  7. ncbi Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology
    Thierry Lequerre
    Department of Rheumatology, Rouen University Hospital, Rouen, France
    J Rheumatol 33:1307-14. 2006

Collaborators

Detail Information

Publications7

  1. ncbi Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia
    Thierry Lequerre
    Department of Rheumatology, Rouen University Hospital and Inserm 905 and Institut Fédératif de Recherche Multidisciplinaire sur les Peptides 23, Institute for Biomedical Research, University of Rouen, 76031 Rouen Cedex, France
    Arthritis Res Ther 11:R99. 2009
    ..Because previous microarray studies have only focused on long-standing (LS) RA compared to osteoarthritis, we aimed to compare the molecular profiles of early and LS RA versus control synovia...
  2. ncbi Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra)
    Carine Bansard
    Department of Rheumatology, University of Rouen, 76031 Rouen Cedex, France
    Rheumatology (Oxford) 50:283-92. 2011
    ..The objective of this study was to predict responsiveness to the anakinra-MTX combination by peripheral blood mononuclear cell gene profiling in order to optimize treatment choice...
  3. ncbi A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs
    Ginette Tenga
    Department of Pharmacy, Rouen University Hospital, 76031 Rouen Cedex, France
    Joint Bone Spine 78:50-5. 2011
    ..We assessed the efficacy, tolerance and cost of a 3 mg/kg starting dose of infliximab for ankylosing spondylitis (AS) and psoriatic arthritis (PsA)...
  4. ncbi Smoking and inflammatory diseases
    Olivier Vittecoq
    Department of Rheumatology, Rouen University Hospital and Inserm U905, Rouen, France
    Best Pract Res Clin Rheumatol 22:923-35. 2008
    ..In both diseases, smoking might interfere with drug efficacy...
  5. ncbi Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort
    Xavier Le Loet
    Rheumatology Department, Rouen University Hospital and Inserm Unit 905, University of Rouen, France
    Rheumatology (Oxford) 50:1901-7. 2011
    ..To test the performances of combining anti-CCP second generation (CCP2) with ACR 1987 classification criteria and to diagnose early RA in a community-based very early arthritis (VErA) patient cohort...
  6. ncbi Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept
    Céline Blache
    INSERM, U905, Institut Fédératif de Recherche Multidisciplinaire surles Peptides 23, Institute for Biomedical Research, University of Rouen, Faculte de Medecine Pharmacie, Rouen, France
    Rheumatology (Oxford) 50:1814-22. 2011
    ..To analyse the therapeutic effects of etanercept (ETA) or adalimumab (ADA) on the numbers and phenotypes of CD4+CD25hi Tregs in RA patients...
  7. ncbi Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology
    Thierry Lequerre
    Department of Rheumatology, Rouen University Hospital, Rouen, France
    J Rheumatol 33:1307-14. 2006
    ..To suggest recommendations for management of acute infusion reactions induced by infliximab in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA)...